---
company: NEUROONE MEDICAL TECHNOLOGIES Corp
ticker: NMTC
form: 8-K
filed: 2026-05-12
accession: 0001213900-26-054744
source: https://www.sec.gov/Archives/edgar/data/1500198/000121390026054744/
---

# NEUROONE MEDICAL TECHNOLOGIES (NMTC) earnings release, May 12, 2026

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) · Form 8-K, Item 2.02 · Filed 2026-05-12 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1500198/000121390026054744/)

NeuroOne Reports Fiscal

Q2 2026 Financial Results and Provides Corporate Business Update

Product Revenue of

$2.4 Million up 72% Year Over Year

Successfully Completed

16 Trigeminal Neuralgia Cases to Date, With All Patients Reportedly Pain Free*

Management to Host

Conference Call Today at 8:30 a.m. Eastern Time

EDEN PRAIRIE, Minn., May 12, 2026

-- NeuroOne

Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results and a business update for the second quarter of fiscal year 2026 ended March 31, 2026.

Company Highlights

Management Commentary

“This was a very productive quarter for

NeuroOne. Product revenue grew 72% year-over-year, we continued to gain clinical experience with our OneRF Trigeminal Neuralgia Ablation

System and have completed 16 procedures to date with all patients reportedly pain free. We continue to be optimistic regarding the advantages and clinical performance of the device for treating facial pain. We also had a peer-reviewed clinical publication validate what physicians using our platform have been telling us – that real-time temperature monitoring during sEEG-guided RF ablation is a meaningful clinical advantage for patients with drug resistant epilepsy.

“At the same time, we executed on the strategic priorities we laid out at the start of the year. We completed our stage 2 ISO 13485 audit, paving the way for international expansion. We regained Nasdaq compliance, restructured our capital base through the reverse stock split, and added a highly experienced executive - David Wambeke, as Chief Business Officer. Also, effective July 1, Christopher Volker will assume the role as our next Chief

Financial Officer. Together, these moves will help to lead our next phase of growth.

“Looking ahead, the catalysts are clear: continued expansion of our OneRF Brain Ablation and Trigeminal Neuralgia Ablation Systems, commercial launch of our drug delivery system in the second half of fiscal 2026 for use in investigational clinical studies or animal studies, continued progress in basivertebral nerve ablation and spinal cord stimulation, and an expanding international footprint as we make progress towards ISO 13485 certification. We are well-positioned for the future and I’m proud of what this team has built.” concluded Dave Rosa, CEO of NeuroOne.

Operational Highlights and Updates

OneRF®

Trigeminal Nerve

Ablation System:² sEEG-Based Drug Delivery Program:

Basi-Vertebral Nerve Ablation

OneRF®

Ablation System in the

Brain:

Spinal Cord Stimulation (SCS) Percutaneous

Paddle Lead Program:

Second Quarter Fiscal 2026 Financial Results

Product revenue was $2.4 million in the second quarter of fiscal 2026, a 72% increase compared to product revenue of $1.4 million in the second quarter of fiscal 2025. The increase was driven by higher sales of OneRF Products. For the six months ended March 31, 2026, product revenue was $5.3 million, an increase of

13% compared to $4.7 million in the same period of the prior fiscal year. The Company had no license revenue in the second quarter or first six months of fiscal 2026, compared to license revenue of $3.0 million in the first six months of fiscal 2025, which was derived from the expanded exclusive distribution agreement with Zimmer.

Product gross profit was $1.3 million, or 53.8% of product revenue, in the second quarter of fiscal 2026, compared to product gross profit of $0.8 million, or 55.6% of product revenue, in the same quarter of the prior fiscal year. For the six months ended March 31, 2026, product gross profit was $2.9 million, or 54.0% of product revenue, compared to $2.7 million, or 57.9% of product revenue, in the same period of the prior fiscal year.

Total operating expenses were $3.4 million in the second quarter of fiscal 2026, compared to $3.5 million in the same quarter of the prior year. Research & Development (R&D) expense in the second quarter of fiscal 2026 was $1.5 million, compared to $1.5 million in the same quarter of the prior year. Selling,

General & Administrative (SG&A) expense in the second quarter of fiscal 2026 was $1.9 million, compared to $1.9 million in the same quarter of the prior year. For the first six months of fiscal 2026, total operating expenses were $6.7 million, compared to $6.7 million in the same period of fiscal 2025. R&D expense in the first six months of fiscal 2026 were $2.9 million, compared to $2.7 million in the same period of fiscal 2025. SG&A expense in the first six months of fiscal 2026 decreased 4% to $3.8 million, compared to $4.0 million in the prior year period.³

Net loss in the second quarter of fiscal 2026 was $2.1 million, or ($0.25) per basic and diluted share, compared to net loss of $2.3 million, or ($0.44) per basic and diluted share, in the same quarter of the prior year. The net loss in the second quarter of fiscal 2025 was favorably impacted by a $0.4 million gain from the fair value change in the warrant liability. For the six months ended March 31, 2026, net loss was $3.5 million, or ($0.42) per basic share and ($0.44) per diluted share, compared to net loss of $0.5 million, or ($0.09) per basic and diluted share, in the same period of the prior year. The lower net loss in the first six months of fiscal 2025 reflected $3.0 million of license revenue recognized in the first quarter of fiscal 2025.

As of March 31, 2026, the Company had cash and cash equivalents of $2.8 million, compared to $6.6 million as of September 30, 2025. The Company also had $2.4 million in accounts receivable... (truncated)ased on normal collection patterns.

The Company had working capital of $5.7 million as of March 31, 2026, compared to working capital of $7.9 million as of September 30, 2025. The Company had no debt outstanding as of

March 31, 2026.

Conference Call and Webcast

Management will host an investor conference call and webcast today, Tuesday, May 12, 2026, at 8:30 a.m. Eastern time to discuss the Company’s fiscal second quarter 2026 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:

Date:

Tuesday, May 12, 2026

Time:

8:30 a.m. Eastern time

U.S. Dial-In (Toll Free):

888-506-0062

International Dial-In:

973-528-0011

Participant Access Code:

224785

Webcast: https://www.webcaster5.com/Webcast/Page/2821/53948

Please join at least five minutes before the start of the call to ensure timely participation.

A playback of the call will be available through Tuesday, May 26, 2026.

To listen to the replay, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 53948. A webcast replay will also be available using the webcast link above through Wednesday, May 12, 2027.⁴

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders.

NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families:

Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation

System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward looking statement that reflects NeuroOne's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward looking statements by the words or phrases

"may," "might," "will," "could," "would," "should," "expect," "intend,"

"plan," "forecasts," "objective," "anticipate," "believe," "estimate," "predict,"

"project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward looking statements may include statements regarding the potential sales of the sEEG-Based

Drug Delivery system in investigational clinical studies or animals in Q3 fiscal 2026, the collaborations with the University of Minnesota and other companies, our ability to obtain ISO 13485 or other regulatory approvals and expand internationally, the collection of accounts receivables, our ability to expand the sales of our OneRF Trigeminal Nerve Ablation System, our and the Company’s ability to expand revenue. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology whether due to supply chain disruptions, labor shortages or otherwise risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology uncertainties inherent in the development process of our technology risks related to changes in regulatory requirements or decisions of regulatory authorities that we may not have accurately estimated the size and growth potential of the markets for our technology risks related to clinical trial patient enrollment and the results of clinical trials that we may be unable to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward looking statements for any reason, even if new information becomes available in the future.

Caution: Federal law restricts this device to sale by or on the order of a physician.

IR Contact

MZ Group – MZ North America

NMTC@mzgroup.us⁵

NeuroOne Medical Technologies Corporation

Condensed Balance Sheets

(Unaudited)⁶... (truncated)echnologies Corporation

Condensed Statements of Operations

(unaudited)⁷

## Financial statements

### Income Statement (For the Three Months Ended — (unaudited))

| | For the Three Months Ended – March 31, – 2026 | For the Three Months Ended – March 31, – 2025 | For the Six Months Ended – March 31, – 2026 | For the Six Months Ended – March 31, – 2025 |
|---|---:|---:|---:|---:|
| Product revenue | 2,391,185 | 1,386,550 | 5,283,820 | 4,660,717 |
| Cost of product revenue | 1,104,568 | 615,489 | 2,429,375 | 1,962,767 |
| Product gross profit | 1,286,617 | 771,061 | 2,854,445 | 2,697,950 |
| License revenue |  |  |  | 3,000,000 |
| Operating expenses: | Selling, general and administrative | 1,919,371 | 1,940,414 | 3,804,826 | 3,983,868 |
| Operating expenses: | Research and development | 1,468,090 | 1,510,663 | 2,857,770 | 2,682,891 |
| Operating expenses: | Total operating expenses | 3,387,461 | 3,451,077 | 6,662,596 | 6,666,759 |
| Operating expenses: | Loss from operations | -2,100,844 | -2,680,016 | -3,808,151 | -968,809 |
| Operating expenses: | Fair value change in warrant liability | -8,271 | 390,351 | 214,469 | 779,796 |
| Operating expenses: | Financing costs |  |  |  | -324,738 |
| Operating expenses: | Other income | 23,446 | 19,058 | 70,123 | 28,466 |
| Operating expenses: | Loss before income taxes | -2,085,669 | -2,270,607 | -3,523,559 | -485,285 |
| Operating expenses: | Net loss | -2,085,669 | -2,270,607 | -3,523,559 | -485,285 |
| Net loss per share (Note 1): | Basic | -0.25 | -0.44 | -0.42 | -0.09 |
| Net loss per share (Note 1): | Diluted | -0.25 | -0.44 | -0.44 | -0.09 |
| Number of shares used in per share calculations (Note 1): | Basic | 8,484,926 | 5,185,075 | 8,436,158 | 5,161,971 |
| Number of shares used in per share calculations (Note 1): | Diluted | 8,484,926 | 5,185,075 | 8,554,213 | 5,161,971 |

### Balance Sheet ((Unaudited))

| | As of – March 31, – 2026 | As of – September 30, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 2,804,011 | 6,570,382 |
| Current assets: | Accounts receivable | 2,426,518 | 1,264,805 |
| Current assets: | Inventory, net | 1,866,633 | 2,226,805 |
| Current assets: | Deferred offering costs | 22,920 | 22,920 |
| Current assets: | Prepaid expenses | 283,716 | 141,372 |
| Current assets: | Total current assets | 7,403,798 | 10,226,284 |
| Current assets: | Intangible assets, net | 33,789 | 44,946 |
| Current assets: | Right-of-use asset | 196,775 | 255,195 |
| Current assets: | Property and equipment, net | 230,596 | 259,222 |
| Current assets: | Total assets | 7,864,958 | 10,785,647 |
| Current liabilities: | Accounts payable | 934,196 | 1,010,369 |
| Current liabilities: | Accrued expenses and other liabilities | 755,258 | 1,292,714 |
| Current liabilities: | Total current liabilities | 1,689,454 | 2,303,083 |
| Current liabilities: | Warrant liability | 709,507 | 1,266,894 |
| Current liabilities: | Operating lease liability, long term | 92,361 | 143,148 |
| Current liabilities: | Total liabilities | 2,491,322 | 3,713,125 |
| Stockholders’ equity: | Common stock, $0.001 par value; 100,000,000 shares authorized; 8,615,532 and 8,334,336 shares issued and outstanding as of March 31, 2026 and September 30, 2025, respectively. | 8,616 | 8,334 |
| Stockholders’ equity: | Additional paid–in capital | 87,498,366 | 85,673,975 |
| Stockholders’ equity: | Accumulated deficit | -82,133,346 | -78,609,787 |
| Stockholders’ equity: | Total stockholders’ equity | 5,373,636 | 7,072,522 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 7,864,958 | 10,785,647 |
